Powell Joshua W, Mann Chelsea A, Toth Paul D, Nolan Sheri, Steinert Anja, Ove Clarissa, Seffernick Justin T, Wozniak Daniel J, Kebriaei Razieh, Lindert Steffen, Osheroff Neil, Yalowich Jack C, Mitton-Fry Mark J
Division of Medicinal Chemistry and Pharmacognosy, Department of Chemistry and Biochemistry, Microbial Infection and Immunity, Division of Outcomes and Translational Sciences, Department of Microbiology, and Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, Ohio 43210, United States.
Department of Biochemistry and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
ACS Med Chem Lett. 2024 Jul 15;15(8):1287-1297. doi: 10.1021/acsmedchemlett.4c00162. eCollection 2024 Aug 8.
Multidrug-resistant bacterial infections pose an ever-evolving threat to public health. Since the outset of the antibacterial age, bacteria have developed a multitude of diverse resistance mechanisms that suppress the effectiveness of current therapies. New drug entities, such as Novel Bacterial Topoisomerase Inhibitors (NBTIs), can circumvent this major issue. A computational docking model was employed to predict the binding to DNA gyrase of atypical NBTIs with novel pharmacophores. Synthesis of NBTIs based on computational docking and subsequent antibacterial evaluation against both Gram-positive and Gram-negative bacteria yielded congeners with outstanding anti-staphylococcal activity and varying activity against select Gram-negative pathogens.
多重耐药细菌感染对公共卫生构成了不断演变的威胁。自抗菌时代开始以来,细菌已形成了多种不同的耐药机制,这些机制抑制了当前疗法的有效性。新型药物实体,如新型细菌拓扑异构酶抑制剂(NBTIs),可以规避这一重大问题。采用计算对接模型来预测具有新型药效团的非典型NBTIs与DNA促旋酶的结合。基于计算对接合成NBTIs,并随后对革兰氏阳性菌和革兰氏阴性菌进行抗菌评估,得到了具有出色抗葡萄球菌活性以及对特定革兰氏阴性病原体具有不同活性的同系物。